To further determine whether the abnormal methylation of p18INK4C is involved in clinical GC progression, we investigated the methylation statuses of 23 individual CpG sites within p18INK4C promoter regions in 25 pairs of GC cases and adjacent non-tumor controls. This evidence concerns the gene CDKN2C and neoplasm.